Effects Of Chlorhexidine Mouthrinse On Peridontopathogens: A Randomized, Placebo-Controlled Study
Information source: Ege University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: This Study Evaluated the Effectiveness of Chlorhexidine Mouthrinse on Subgingival Microbiota
Intervention: Chlorhexidine gluconate (Drug); Placebo mouthrinse (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Ege University
Summary
The aim of this study is to evaluate the therapeutic effectiveness of chlorhexidine
mouthrinse on gingival inflammation and subgingival microbiota in addition to daily
mechanical plaque control in a population with established gingivitis.
Clinical Details
Study design: N/A
Primary outcome: effectiveness of chlorhexidine mouthrinse on gingival inflammation and subgingival microbiota in addition to daily mechanical plaque controleffectiveness of chlorhexidine mouthrinse subgingival microbiota in addition to daily mechanical plaque control
Detailed description:
Failure to perform oral hygiene adequately at the gingival margin results in the formation
of a pathogenic plaque that has the potential to initiate gingivitis and in some individuals
to progress to periodontitis. However, factors, such as dexterity and motivation, can limit
the effectiveness of daily self-performed oral hygiene. The use of a chemical
plaque-inhibitory mouthrinse as an adjunct to toothbrushing may improve the oral health of
individuals who are inadequate in mechanical plaque control in maintaining gingival health.
Chlorhexidine (CHX) has been effectively used in the treatment of gingival inflammation and
can be considered as the gold standard for oral antiseptics.
The effectiveness of CHX in reducing the formation of dental plaque and preventing
gingivitis in addition to professional mechanical debridement were studied in several
clinical studies, but there is limited number of studies investigating the effects of CHX on
untreated gingivitis and subgingival microbiota.
Eligibility
Minimum age: 18 Years.
Maximum age: 45 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- 18-45 years old male or female with gingivitis associated with dental plaque, no
clinical signs of destructive periodontal disease, clinical attachment loss < 3mm, a
minimum of 20 teeth (teeth that have gross caries, were fully crowned or extensively
restored, orthodontic banded, abutments, or third molars were not included in the
tooth count).
Exclusion Criteria:
- use of tobacco products, history or current manifestation of systemic disease which
could impair immune response such as diabetes mellitus, immunological disorders,
hepatitis and HIV infections, use of antibiotic or anti-inflammatory or
immunosuppressive drugs during 3 months period prior to the start of the trial,
periodontal therapy during the last 3 month, pregnancy or lactation and oral
contraceptives usage.
Locations and Contacts
Ege U School of Dentistry, Izmir, Bornova 35100, Turkey
Ege University School of Dentistry Dep of Periodontology, Izmir, Bornova 35100, Turkey
Additional Information
Starting date: March 2006
Last updated: October 1, 2010
|